Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)

Detaylı Bibliyografya
Asıl Yazarlar: Hillmen, P, Pettitt, A, Schuh, A, Milligan, D, Bowles, K, Bareford, D, Riaz, J, Follows, G, Rule, S, Wallis, J, Gribben, J, Noble, R, Pocock, C, Lisby, S, Carey, J, Gupta, I, Chang, C, McKeown, A
Materyal Türü: Journal article
Baskı/Yayın Bilgisi: 2014

Benzer Materyaller